The KANK1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the KANK1 gene in the Jurkat T-lymphocyte line. This gene-disruption model enables loss-of-function studies without clonal selection, offering a heterogeneous genetic background that mirrors population-level responses. The polyclonal format avoids artifacts associated with single-cell clones and is ideal for functional genomics and signaling analyses.
Jurkat cells are an immortalized human T lymphocyte line derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia. They are widely employed to study T-cell receptor signaling, leukemia biology, and immune responses. Their leukemic origin provides a relevant context for investigating oncogenic mechanisms, and they are amenable to genetic modification, making them suitable for knockout studies of tumor suppressors such as KANK1.
KANK1 is a scaffolding protein that negatively regulates RhoA, a central GTPase controlling actin dynamics. It interacts with Liprin-??1 and Talin at focal adhesions and is transcriptionally activated by p53 and TGF-??. KANK1 loss leads to RhoA overactivation, driving ROCK-mediated phosphorylation of LIMK and Cofilin, which stabilizes F-actin and promotes stress fiber formation. Additionally, KANK1 modulates ??-catenin signaling, linking cytoskeletal organization to gene expression. This places KANK1 at a critical intersection of adhesion signaling, cytoskeletal remodeling, and transcriptional control.
In Jurkat T-cell leukemia cells, KANK1 knockout removes a brake on RhoA activity, triggering actin cytoskeletal reorganization that alters cell adhesion and migration. These changes may enhance T-cell receptor signaling and promote leukemic cell behavior, making the model valuable for dissecting tumor suppressor functions in lymphocytes. The polyclonal population captures a spectrum of editing events, allowing assessment of phenotypic consistency and functional domain requirements.
Typical applications include Western blotting and immunofluorescence to confirm KANK1 loss and actin architecture changes, RhoA activation assays to quantify GTP-bound RhoA, transwell migration and adhesion assays to measure motility, and flow cytometry for surface marker profiling. The cells also support drug screening for Rho-ROCK inhibitors and mechanistic studies of T-cell signaling. For further details or to order, contact Ascent Research.
